摘要
目的比较替格瑞洛与氯吡格雷治疗急性冠脉综合征(ACS)的临床疗效和安全性。方法将医院收治的120例ACS患者随机分为研究组和对照组,各60例。两组患者均给予常规治疗,研究组加用替格瑞洛,对照组加用氯吡格雷。比较两组患者的临床疗效、心血管不良事件(MACE)及不良反应发生率。结果研究组有效率为92.67%,显著高于对照组的80.00%,差异有统计学意义(P<0.05);研究组的MACE发生率为2.00%,对照组为2.67%,差异无统计学意义(P>0.05);研究组的不良反应发生率为3.33%,低于对照组的10.67%,组间差异有统计学意义(P<0.05)。结论替格瑞洛治疗ACS可有效改善患者的临床症状,效果优于氯吡格雷,可降低ACS患者的不良反应发生率,且不增加出血风险,值得临床推广。
Objective To discuss the clinical efficacy and safety of Ticagrelor and Clopidogrel for acute coronary syndrome（ACS）.Methods 120 patients of ACS were selected and divided into the study group and the control group, 60 cases in each group. Both groups were given routine treatment. The study group was added with Ticagrelor and the control group was added with Clopidogrel. The clinical efficacy,the incidence of cardiovascular adverse events（MACE） and the incidence of adverse events were compared between the two groups. Results The total effective rate was 92. 67 % in study group, which was significantly higher than 80. 00 % in the control group（P〈 0. 05）; the MACE incidence rate was 2. 00% in the study group,and 2. 67% in the control group,which indicated no significant difference（P〉 0. 05）. The incidence of adverse reactions was 3. 33% in the study group, which was significantly lower than 10. 67% in the control group（P〈 0. 05）. Conclusion Ticagrelor can improve the clinical symptoms of patients with better efficacy than clopidogrel,can reduce the incidence of adverse reactions in ACS patients and do not increase the risk of bleeding,which is worthy of clinical promotion.
出处
《中国药业》
CAS
2017年第5期47-48,共2页
China Pharmaceuticals
作者简介
第一作者：欧武华（1973-），男，主管药师，研究方向为医院药学，（电话）0755—25509566（电子信箱）2225370481@qq．com。
通讯作者：李东，男，主任药师，研究方向为临床药学，（电话）0755—22942817（电子信箱）szlidong@126．com。
